"A phase II, randomized, double-blind, parallel-group, placebo-controlled, oral food challenge trial of XOLAIR® (omalizumab) in peanut allergy (TOPS)" (vol 119, pg S117, 2007)

被引：0
|
作者：
Sampson, H. A. [1 ]
Leung, D. Y. M.
Burks, A. W.
Lack, G.
Bahna, L.
Jones, S. M.
Varchavsky, J.
Wong, D. A.
Deniz, Y.
机构：
[1] Mt Sinai Sch Med, New York, NY 10029 USA
[2] Natl Jewish Med & Res Ctr, Denver, CO USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] St Marys Hosp, London, England
[5] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA
[6] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[7] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2007年 / 119卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1025 / 1025
页数：1
相关论文
共 50 条
  • [1] A phase II, randomized, double-blind, parallel-group, placebo-controlled, oral food challenge trial of XOLAIR® (omalizumab) in peanut allergy (TOPS)
    Sampson, H. A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S117 - S117
  • [2] A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy
    Sampson, Hugh A.
    Leung, Donald Y. M.
    Burks, A. Wesley
    Lack, Gideon
    Bahna, Sami L.
    Jones, Stacie M.
    Wong, Dennis A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (05) : 1309 - U338
  • [3] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Pasquale Caponnetto
    Davide Campagna
    Jasjit S. Ahluwalia
    Christopher Russell
    Marilena Maglia
    Paolo Marco Riela
    Carmelo Fabio Longo
    Barbara Busa
    Riccardo Polosa
    BMC Medicine, 21
  • [4] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Caponnetto, Pasquale
    Campagna, Davide
    Ahluwalia, Jasjit S.
    Russell, Christopher
    Maglia, Marilena
    Riela, Paolo Marco
    Longo, Carmelo Fabio
    Busa, Barbara
    Polosa, Riccardo
    BMC MEDICINE, 2023, 21 (01)
  • [5] Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
    Venhoff, Nils
    Schmidt, Wolfgang
    Bergner, Raoul
    Rech, Juergen
    Unger, Leonore
    Tony, Hans-Peter
    Mendelson, Meryl
    Sieder, Christian
    Maricos, Meron
    Thiel, Jens
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 4130 - 4133
  • [6] A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil W.
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas L.
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Chin, Peter
    Garren, Hideki
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 17
  • [7] Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
    Keary, Christopher
    Bird, Lynne M.
    de Wit, Marie-Claire
    Hatti, Shivkumar
    Heimer, Gali
    Heussler, Helen
    Kolevzon, Alexander
    Mathews, Adera
    Ochoa-Lubinoff, Cesar
    Tan, Wen-Hann
    Yan, Ying
    Adams, Maxwell
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 47 : 6 - 12
  • [8] Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
    Burge, James
    Sansone, Valeria
    McDermott, Michael
    Smith, Patty
    Herr, Barbara
    Tawil, Alrabi
    Pandya, Shree
    Kissel, John
    Ciafaloni, Emma
    Shieh, Perry
    Ralph, Jeffrey
    Amato, Anthony
    Cannon, Stephen
    Trivedi, Jaya
    Barohn, Richard
    Crum, Brian
    Mitsumoto, Hiroshi
    Pestronk, Alan
    Meola, Giovanni
    Conwit, Robin
    Jasek, Mark
    Hanna, Michael
    Griggs, Robert
    NEUROLOGY, 2016, 86
  • [9] A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy of Omalizumab in Prevention of Bronchoconstriction Following Environmental Aeroallergen Exposure
    Corren, J.
    Wood, R. A.
    Patel, D.
    Zhu, J.
    Fish, J. E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB72 - AB72
  • [10] Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
    Genovese, Mark C.
    Jarosova, Katerina
    Cieslak, Dorota
    Alper, Jeffrey
    Kivitz, Alan
    Hough, Douglas R.
    Maes, Peter
    Pineda, Lilia
    Chen, Mindy
    Zaidi, Farrukh
    ARTHRITIS & RHEUMATOLOGY, 2015, 67 (07) : 1703 - 1710
12345